Business Description
Adaptimmune Therapeutics is a UK-based biopharmaceutical company focused on developing advanced cell therapies for cancer patients in the United States and United Kingdom. Its lead product, TECELRA, is an approved T-cell therapy for adults with a rare and difficult-to-treat form of soft tissue cancer called synovial sarcoma, while several other treatments are in various stages of clinical development targeting additional cancer types. The company works alongside notable partners including Galápagos, Noile-Immune Biotech, and MD Anderson Cancer Center to advance its research and expand its therapeutic reach.
